Lenalidomide after stem-cell transplantation for multiple myeloma.

ABSTRACT:

Background

Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma.

Methods

Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15).

Results

The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding,

SUBMITTER: McCarthy PL 

PROVIDER: S-EPMC3744390 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature